A lower effective dose may exist in a sleep-fragmented subgroup if the beneficial mechanism is indirect, via improved slow-wave sleep rather than direct ISR rescue. This is clinically feasible and testable, but current support is stronger for symptomatic sleep benefit than for true disease modification.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["CSF Arterial Inflow Periarterial Space"]
B["AQP4 on Astrocyte Endfeet Perivascular Polarization"]
C["Glymphatic Flow ISF Convective Clearance"]
D["Abeta/Tau Efflux Perivenous Drainage"]
E["Lymphatic Outflow Cervical Lymph Nodes"]
F["AQP4 Mislocalization in AD/Aging"]
G["Reduced ISF Clearance Aggregate Accumulation"]
A --> B
B --> C
C --> D
D --> E
F -.->|"impairs"| C
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for HTR2A; HRH1; AQP4 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
4
MECH 3CLIN 4GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Low-dose trazodone improved sleep parameters in pa…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF trazodone 50-100mg nightly is administered to Alzheimer's disease patients with PSG-confirmed marked slow-wave sleep deficiency (NREM stage 3 < 10% of total sleep time), THEN their slow-wave sleep percentage will increase by at least 5 absolute percentage points within 4 weeks of treatment.
pendingconf: 0.35
Expected outcome: Mean NREM stage 3 percentage increases from baseline <10% to ≥15% in the SWS-deficient group
Falsified by: No statistically significant increase in NREM stage 3 percentage (p > 0.05) or absolute increase < 5 percentage points in the marked SWS-deficient subgroup after 4 weeks of low-dose trazodone
Method: Randomized controlled trial in NHANES or comparable dementia cohort with polysomnography-confirmed baseline SWS deficiency; patients stratified into marked deficiency (<10% N3) versus mild/no deficiency (≥10% N3); trazodone 50-100mg nightly versus placebo for 4 weeks; primary outcome measured by in-laboratory PSG at week 4
IF the dose-response relationship for sleep improvement is subgroup-dependent, THEN Alzheimer's disease patients with marked SWS deficiency (<10% NREM3 at baseline) will show clinically meaningful improvement in Pittsburgh Sleep Quality Index (PSQI reduction ≥3 points) at trazodone 50-100mg, while patients without marked SWS deficiency will NOT achieve PSQI reduction ≥3 points at the same low dose.
pendingconf: 0.30
Expected outcome: PSQI reduction ≥3 points in ≥60% of SWS-deficient patients versus <30% of non-deficient patients at 50-100mg trazodone
Falsified by: Non-markedly deficient patients (baseline NREM3 ≥10%) demonstrate equal or greater PSQI improvement (≥3 point reduction) as the SWS-deficient subgroup at 50-100mg trazodone, indicating dose-requirement is NOT subgroup-dependent
Method: Pre-planned subgroup analysis of a randomized trial (e.g., NIH funded ADRD cohort) comparing trazodone 50-100mg nightly across dementia patients stratified by baseline PSG-measured slow-wave sleep deficiency; PSQI assessed at baseline and 8 weeks; interaction test for subgroup × treatment effect
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
HTR2A; — Search for structure
Click to search RCSB PDB